Clinical Trial

Efficacy of Hi-tACS for Schizophrenia Negative Symptoms

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated June 4, 2025 (before its estimated November 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to investigate whether Hi-tACS is effective and safe in treating negative symptoms of schizophrenia. Schizophrenic patients will receive treatment (Hi-tACS or shame stimulation) for 2 weeks. Negative symptoms, cognitive functioning, social functioning, and quality of life of intervention group and control group were assessed and compared between the two groups at baseline, 2 weeks, and 3 months post-intervention.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-03-16; most recent amendment 2025-05-29.
Trial Details
NCT Number NCT06888726
Lead Sponsor Shanghai Mental Health Center
Conditions Schizophrenia; Negative Type, Transcranial Alternating Current Stimulation
Enrollment 60 participants
Start Date 2024-06-27
Primary Completion 2025-11-30 (estimated)
Study Completion 2026-11-30 (estimated)
Updated on ClinicalTrials.gov 2025-06-04